|
Mar 13, 2023
|
Innoviva Announces FDA Advisory Committee Meeting to Review Sulbactam-Durlobactam (SUL-DUR), an Investigational Targeted Antibiotic
|
|
|
Feb 28, 2023
|
Innoviva Reports Fourth Quarter 2022 Financial Results and Highlights Recent Company Progress
|
|
|
Jan 10, 2023
|
Armata Pharmaceuticals Announces Closing of $30 Million Secured Convertible Credit Agreement with Innoviva Strategic Opportunities LLC
|
|